ERBB2 and cancer: We showed that ebselen oxide can suppress the activity of HER2 harboring V777L or V842I mutations that were found, respectively, in 4.0% and 4.4% of all cancers [25] and, due to its mechanism of action, it is also expected to act on other HER2 alterations.